Phosphate binder
Phosphate binders are medications used to reduce the absorption of dietary phosphate; they are taken along with meals and snacks.
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Phosphate binders are medications used to reduce the absorption of dietary phosphate; they are taken along with meals and snacks. They are frequently used in people with chronic kidney failure (CKF), who are less able to excrete phosphate, resulting in an elevated serum phosphate.
Mechanism of action
These agents work by binding to phosphate in the GI tract, thereby making it unavailable to the body for absorption. Hence, these drugs are usually taken with meals to bind any phosphate that may be present in the ingested food.
Phosphate binders may be simple molecular entities (such as magnesium, aluminium, calcium, or lanthanum salts) that react with phosphate and form an insoluble compound. Calcium carbonate Calcium-based phosphate binders, such as calcium carbonate, directly decrease phosphate levels by creating insoluble calcium–phosphate complexes which gets eliminated in the feces.
Lanthanum carbonate Non-calcium-based phosphate binders, including lanthanum carbonate, form insoluble complexes with phosphates in food, thereby reducing the amount of phosphate in the body. Sevelamer carbonate Sevelamer is an insoluble polymeric amine, which is protonated once in the intestines and this allows it to bind dietary phosphate.
Phosphates are eliminated along with sevelamer, leading to a decrease in the body's phosphate levels.
Medical use
For people with chronic kidney failure, controlling serum phosphate is important because it is associated with bone pathology and regulated together with serum calcium by the parathyroid hormone (PTH).
Adverse effects
Calcium carbonate GI effects (nausea, vomiting, constipation) Risk of cardiovascular calcification Risk of hypercalcemia Lanthanum carbonate GI obstruction Bile duct obstruction Hepatic impairment No hypercalcemia risk Sevelamer carbonate GI effects (nausea, vomiting, constipation, flatulence) No hypercalcemia risk
Choice of agent
There have been limited trials comparing phosphate binders to placebo in the treatment of hyperphosphatemia in people with chronic kidney disease. When compared with people receiving calcium-based binders, people taking sevelamer have a reduced all-cause mortality.
Types
Calcium acetate/magnesium carbonate
References
Lederer E, Ouseph R, Erbeck K. Hyperphosphatemia, eMedicine.com, URL: Hyperphosphatemia: Practice Essentials, Background, Pathophysiology, Accessed on July 14, 2005.
External links
High Phosphate Control - Official Fosrenol Homepage Phosphate Binders: What Are They And How Do They Work? - American Association of Kidney Patients* Phosphate Binders - National Kidney Foundation Phosphate Binders - Northwest Kidney Centers - a center that provides services for people with ESRD in the Seattle area. High Phosphate - Phosphorus Control - Information for healthcare professionals on the treatment and management of hyperphosphatemia
Common Phosphate Binders
Lanthanum - medlineplus.org Sevelamer - medlineplus.org Sevelamer - Renvela.com
Text derived from https://en.wikipedia.org/w/index.php?oldid=1329398447 under CC BY-SA 4.0; modifications have been made.